Recombinant human nerve growth factor: Phase I/II started

Dompe began the double-blind, placebo-controlled, international Phase I/II REPARO trial to evaluate 10 and 20 ug/ml rhNGF eye drop solution given 6 times daily for 8 weeks in about 174 patients with s...